Design of floating bilayer tablets of diltiazem hydrochloride and lovastatin.

PDA J Pharm Sci Technol

Satara College of Pharmacy, Plot no. 1539, New MIDC, Degaon, Satara, M.S., India.

Published: January 2009

The purpose of the study is to design bilayer floating tablets of diltiazem HCI and lovastatin to give immediate release of lovastatin and controlled release of diltiazem HCl and to study the influence of presence of one drug on the release pattern of other drug. The bilayer tablets consist of sodium starch glycolate as superdisintegrant for lovastatin in the immediate release layer and hydroxypropyl methylcellulose (HPMC) K4M and Xanthan gum as release-retarding agents for diltiazem HCl in the controlled release layer. Sodium bicarbonate was used as the gas generating agent. Dicalcium phosphate was used as the channeling agent. The direct compression method was employed for preparation of the bilayer tablets. Various physicochemical parameters were evaluated for the prepared tablets. The physicochemical parameters were found to be within range. There was significant difference in drug release and floating lag time (P < 0.05). All the formulations showed good matrix integrity. All the formulations released lovastatin within 30 min. The diffusion exponent for diltiazem HCl was found to be independent of polymer concentration. The release pattern of diltiazem HCI was fitted to different models based on coefficient of correlation (R). All the formulations followed the Higuchi model, except F1 which followed the Peppas model. HPMC K4M and Xanthan gum retarded the release of diltiazem HCl for 12 h. The release of one drug remained unaffected in presence of the other drug. In conclusion, such kind of combined dosage forms can effectively be formulated to deliver more than one drug so as to have improved patient compliance and better disease management.

Download full-text PDF

Source

Publication Analysis

Top Keywords

diltiazem hcl
16
bilayer tablets
12
release
9
tablets diltiazem
8
diltiazem hci
8
lovastatin release
8
controlled release
8
release diltiazem
8
presence drug
8
drug release
8

Similar Publications

Looking at the albumin-drug binding via partitioning in aqueous two-phase system.

Biochem Biophys Res Commun

December 2024

Cleveland Diagnostics, 3615 Superior Ave., Cleveland, OH, 44114, USA. Electronic address:

The partition coefficient of human serum albumin (HSA) was analyzed in the PEG600-Dex70, 0.15 M NaCl/KCl in 0.01 M Na/K phosphate buffer, pH 7.

View Article and Find Full Text PDF

Background: High output is a common cause for readmission after new ileostomy creation. The loss of sodium leads to compensatory activation of the renin-angiotensin-aldosterone system (RAAS). Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are first-line therapy for hypertension in the United States.

View Article and Find Full Text PDF

Efficacy and safety of different antiarrhythmic protocols used for rate control in dogs with secondary atrial fibrillation.

J Vet Cardiol

November 2024

Department of Animal Medicine, Production and Health, University of Padova, Viale dell'Università 16, 35020, Legnaro, Italy.

Introduction/objectives: Studies comparing the effects of antiarrhythmic protocols used for rate control in dogs with secondary atrial fibrillation (AF) are currently limited; therefore, this study aimed to report detailed data on the efficacy and therapy-related side-effects (TRSEs) of different antiarrhythmic protocols in dogs with secondary AF.

Animals, Materials, And Methods: Dogs with secondary AF treated with combination therapy with diltiazem and digoxin (CT), diltiazem monotherapy (MT), digoxin monotherapy (MT), or amiodarone monotherapy (MT) were retrospectively evaluated. Signalment, clinical, diagnostic, therapeutic, and outcome data were retrieved.

View Article and Find Full Text PDF

While drug-drug interactions (DDIs) and their pharmacokinetic (PK) mechanisms are well-studied prior to drug approval, severe adverse drug reactions (SADRs) caused by DDIs often remain underrecognized due to limitations in pre-marketing clinical trials. To address this gap, our study utilized a literature database, applied natural language processing (NLP) techniques, and conducted multi-source electronic health record (EHR) validation to uncover underrecognized DDI-SADR signals that warrant further investigation. PubMed abstracts related to DDIs from January 1962 to December 2023 were retrieved.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!